Source: Korea Newswire

Press Release: GeneTex : GeneTex Launches SARS-CoV-2 Variant Spike RBD ACE2 Binding Activity-Neutralization Assay Panel

GeneTex, a leading international research antibody manufacturer, continues to expand and diversify its nearly comprehensive portfolio of SARS-CoV-2/COVID-19 reagents. Recently, the company has focused on developing products to help overcome the viral variants that threaten to undermine the social distancing measures and vaccination programs designed to end the pandemic. These efforts have culminated in the creation of GeneTex's SARS-CoV-2 (COVID-19) RBD ACE2 Binding Activity / Neutralization Ass...

Read full article »
Est. Annual Revenue
$25-100M
Est. Employees
25-100
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more